Bevacizumab-Based Therapies in Malignant Tumors-Real-World Data on Effectiveness, Safety, and Cost

• Published in: Cancers Vol. 16; no. 14; p. 2590
• Main Authors: Chitoran, Elena, Rotaru, Vlad, Ionescu, Sinziana-Octavia, Gelal, Aisa, Capsa, Cristina-Mirela, Bohiltea, Roxana-Elena, Mitroiu, Madalina-Nicoleta, Serban, Dragos, Gullo, Giuseppe, Stefan, Daniela-Cristina, Simion, Laurentiu
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 19.07.2024
• Subjects: Amino acids; Angiogenesis; Bevacizumab; Biological products; Breast cancer; Cancer; Cancer patients; Cancer therapies; Chemotherapy; Clinical outcomes; Clinical trials; Development and progression; Economic aspects; FDA approval; Glioma; Hypoxia; Kinases; Medical prognosis; Medical research; Medicine, Experimental; Metastasis; Monoclonal antibodies; Non-small cell lung carcinoma; Oncology; Ovarian cancer; Patients; Permeability; Respiratory agents; Safety and security measures; Small cell lung carcinoma; Thromboembolism; Tumor necrosis factor-TNF; Tumorigenesis; Tumors; Vascular endothelial growth factor; Wound healing; Romania; cancer metabolism; oncologic outcomes; VEGF; survival; angiogenesis inhibitors; recombinant humanized monoclonal antibody; real-world experience; targeting metabolic vulnerabilities; Avastin; Bevacizumab; therapy-specific adverse effects
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16142590

Overall, it is estimated that more than 3,500,000 patients have received Bevacizumab as part of systemic oncologic treatment. Bevacizumab and its biosimilars are currently marketed in over 130 countries. Given the wide usage of Bevacizumab in current oncological practice, it is very important to compare the "real-world" results to those obtained in controlled clinical trials. This study aims to describe the clinical experience of using Bevacizumab in a large cohort of cancer patients in "non-controlled real-world" conditions with regard to effectiveness, safety, and cost of therapy. For this purpose, we conducted an open, observational, retrospective study involving all patients treated for solid malignant tumors in the Bucharest Institute of Oncology with "Prof. Dr. Al. Trestioreanu" with Bevacizumab-based systemic therapy, between 2017 and 2021. The study consisted of 657 treatment episodes in 625 patients (F/B = 1.62/1, with a median age of 57.6 years) which were treated for malignant tumors (majority colorectal, non-small cell lung, ovarian, and breast cancer). First-line treatment was administered in 229 patients, and the rest received Bevacizumab as second or subsequent lines of treatment. The overall response rate to Bevacizumab-based therapies was around 60-65% across all indication except for subsequent treatment lines in colorectal and ovarian cancers, where lower values were recorded (27.1%, and 31.5% respectively). Median PFS for the entire cohort was 8.2 months (95% CI 6.8-9.6), and the median OS was 13.2 months (95% CI 11.5-14.9). Usual bevacizumab-related toxicities were observed, including bleeding, hypertension, wound-healing complications, gastrointestinal perforation, other types of fistulas, septic complications, and thromboembolic events. Although the clinical benefits are undeniable, the addition of Bevacizumab to standard chemotherapy increased the overall treatment cost by 213%. Bevacizumab remains a high-cost therapy, but it can add to clinical benefits (like overall survival, progression-free survival, and response rate) when used in conjunction with standard chemotherapy. Similar results as those presented in various controlled trials are observable even on unselected cohorts of patients in the uncontrolled conditions of "real-world" oncological practice. Off-label usage is encountered in clinical practice, and this aspect should be monitored given the potential adverse effects of the therapy.